FRRS1L

Across TCGA pan-cancer cohorts, FRRS1L RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of FRRS1L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FRRS1L RNA is repressed in tumor relative to normal tissue. In most cancer types FRRS1L is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, COAD, and STAD are the cancer types where FRRS1L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FRRS1L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	−0.139	<.001	12	view →
COAD	Male	II,III,IV	−0.764	<.001	11	view →
STAD	All	All	−1.414	<.001	7	view →
UCEC	All	II,III,IV	−2.489	<.001	6	view →
BRCA	Female	II,III,IV	−0.391	<.001	6	view →
THCA	Male	III,IV	−0.658	<.001	4	view →
KIRP	Male	All	−0.077	.002	4	view →
READ	All	All	−1.023	<.001	3	view →
PRAD	All	All	−0.775	<.001	2	view →
LUSC	Male	All	+0.622	<.001	2	view →
LIHC	All	All	+0.246	.018	2	view →
KICH	Male	III,IV	−0.137	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

FRRS1L–KIRC

Open the KIRC breakdown →